Treatment of Stage I- II Nasopharyngeal Carcinoma with Late Course Accelerated Hyperfractionation Radiotherapy
10.3321/j.issn:1000-467X.2001.02.015
- VernacularTitle:后程加速超分割放射治疗I～II期鼻咽癌的疗效观察
- Author:
Xiao-Dong ZHU
1
;
An-Yu WANG
;
Ling LI
;
Hai-Jie LU
;
Long CHEN
;
Zhen-Qiang LIANG
;
Shi-Xiong LIANG
;
Yun-Li YANG
;
Chun-Hua WU
Author Information
1. Guangxi Cancer Hospital
- From:Chinese Journal of Cancer
2001;20(2):180-182
- CountryChina
- Language:Chinese
-
Abstract:
Objective: The current study was designed to observe the clinical results of late course accelerated hyperfractionation(LCAH) radiotherapy in Stage I- II nasopharyngeal carcinoma(NPC) patients. Methods: A total of 108 patients with Stage I- II NPC were divided at random into two groups: conventional fractionation(CF) and LCAH, The patients in CF group received a fraction of 2 Gy daily, 5 days per week, to total dose of 70 Gy/7weeks. The patients in LCAH group were treated with the same fractionation as CF group to dose of 36- 40 Gy, and followed by late course accelerated hyperfractionation radiotherapy: 1.5 Gy, twice daily, with the interval of 6 hours between fractions, to total dose of 69 Gy/6weeks. Results: The complete response rate in the nasopharynx was 89.47％ in the LCAHR and 70.97％ in the CFR at the end of the course (P=0.05). Disappeared rate of cervical lesion was not significant different between two groups (P >0.05). The survival rates of 1, 2, and 3-year were 98.13％ ,93.95％ ,90.87％ in the LCAH and 96.12％ ,80.97％ ,78.55％ in the CF, respectively (P=0.06). There was no significant difference in radiation reaction and sequela between two groups( P >0.05) . Conclusion: The clinical results of LCAH radiotherapy in Stage I- II NPC may be better than conventional fractionation radiotherapy, is worth further study.
